Curaleaf Clears Final Regulatory Hurdles in Contested Aurora Cannabis Bid
Curaleaf has secured all German and Canadian competition clearances for its Aurora Cannabis bid, sharpening its contest with Organigram's C$561 million rival deal ahead of a December 4 offer expiry.
By Nathan Brooks
3 min read

What's News
- Canada's Competition Bureau issued a no-action letter on November 2, 2026.
- Germany's Federal Cartel Office confirmed clearance on November 3, 2026.
- Curaleaf's enhanced offer, announced October 6, expires December 4, 2026.
- Organigram's rival deal values Aurora at approximately C$561 million fully diluted.
- Germany and Canada were the only jurisdictions requiring competition clearance.
Curaleaf Holdings has secured every competition law clearance it needs for its proposed acquisition of Aurora Cannabis, with regulators in Germany and Canada both greenlighting the deal within a two-week window. Germany's Federal Cartel Office confirmed on November 3 that the proposed acquisition did not meet the conditions for prohibition under German competition law.
Germany and Canada were the only two jurisdictions where Curaleaf's proposal required competition clearance. That makes this week's confirmations the full set, not a partial milestone.
The regulatory sequence unfolded in three steps. On October 20, 2026, Germany's Federal Ministry for Economic Affairs and Energy approved the acquisition of Aurora's German operating entities — Aurora Europe, Aurora Deutschland, and Aurora Produktions. On November 2, Canada's Competition Bureau issued a no-action letter on Curaleaf's proposed purchase of Aurora shares, saying it had completed its review and did not currently intend to challenge the deal under the applicable provision of the Competition Act. A day later, the Federal Cartel Office closed the loop.
What does this change for Aurora shareholders?
It removes a real obstacle, but it doesn't close anything. Curaleaf's enhanced takeover offer, announced October 6, remains outstanding and is scheduled to expire on December 4, 2026, unless withdrawn or amended. Completion still depends on the satisfaction or waiver of the remaining conditions.
The timing matters because Aurora is weighing a competing proposal. Organigram previously announced an agreement to acquire Aurora in a transaction valuing the company at approximately C$561 million on a fully diluted equity basis. That arrangement offers Aurora shareholders different combinations of cash and shares — and it remains subject to shareholder, court, regulatory, and other approvals.
So Aurora shareholders are effectively comparing two unfinished deals. Curaleaf's argument is that its regulatory homework is done; Organigram's still isn't. Curaleaf said its completed competition reviews provide greater certainty regarding the potential closing of its own proposal, and the company is leaning on that regulatory progress as shareholders weigh the alternatives.
Boris Jordan, Chairman and CEO of Curaleaf Holdings, put it bluntly: "With all required competition law clearances secured, the path is clear for Aurora shareholders to realize the value our Offer provides. We appreciate the constructive engagement of the regulators who reviewed the transaction."
Why two multi-market operators are fighting over Aurora
The competing bids reflect interest in combining businesses with established medical and recreational cannabis operations across international markets. Aurora has built a significant presence in medical cannabis, including operations serving European markets — exactly the geography where Curaleaf has been expanding.
Curaleaf operates consumer and medical cannabis businesses in North America and internationally, with production, distribution, and commercial relationships across Europe, Canada, and Australasia. Its brand portfolio includes Curaleaf, Select, Grassroots, Dark Heart, and Anthem.
A combination with Aurora could hand Curaleaf additional assets and capabilities across regulated cannabis markets. But any of those benefits depend on successful completion and integration — and completion is anything but assured while the takeover contest remains active.
What happens next
The December 4 expiry date is now the anchor for the whole contest. Curaleaf's offer stays subject to its existing terms and completion requirements, and the company believes its finished regulatory process gives shareholders an important consideration as they evaluate the proposals.
The outcome will come down to shareholder decisions and the remaining conditions attached to the competing offers. For practitioners tracking the deal, the practical question is simple: does Organigram secure its own approvals before Curaleaf's offer expires, or does the December 4 deadline force Aurora holders to choose between a fully cleared bid and a partially cleared one?
Source: pulse2.com
More from Nathan Brooks
Show full bio
News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.
2,232 articles